Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 680-702

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Kim, Jong Hoon ^a   Burns, Cara C ^b   Kew, Olen M ^b   Oberste, M Steven ^b   Diop, Ousmane M ^c   Wassilak, Steven G F ^d   Cochi, Stephen L ^d   Thompson, Kimberly M ^a,e  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dynamic modeling; Outbreak risks; Poliovirus

Indexed keywords

DIRECT OBSERVATIONS; EVOLUTION PROCESS; GENETIC SEQUENCE; GLOBAL SURVEILLANCE; POLICY MAKERS; POLIOVIRUS; POTENTIAL MODEL; RISK FACTORS;

DYNAMIC MODELS; POPULATION STATISTICS; RISK MANAGEMENT; VIRUSES;

VACCINES;

ORAL POLIOMYELITIS VACCINE;

IMMUNITY; LITERATURE REVIEW; NUMERICAL MODEL; POLICY MAKING; POLIOMYELITIS; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; VACCINATION; VACCINE; VIRULENCE; VIRUS;

ARTICLE; HUMAN; IMMUNOLOGY; POLIOMYELITIS; THEORETICAL MODEL; VIROLOGY;

HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL;

POLIOVIRUS;

EID: 84875935010     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12022     Document Type: Article

References (145)

1. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines, 5th ed. Saunders Elsevier, 2008.
2. Salk JE. Requirements for persistent immunity to poliomyelitis. American Journal of Medical Science, 1956; 232(4):369-377.
3. Hammon WM, Ludwig EH. Possible protective effect of previous type 2 infection against paralytic poliomyelitis due to type 1 virus. American Journal of Hygiene, 1957; 66(3):274-280.
4. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA. Seroprevalence of antibody against poliovirus in inner-city preschool children. Journal of the American Medical Association, 1996; 275(21):1639-1645.
5. Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E. Lesson from Cuba: Mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 1994; 72(2):221-225.
6. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Barrera Ora J, Ben-Porath E, Rennick V. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. American Journal of Epidemiology, 1967; 86(1):112-136.
7. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 2013; 33(4):647-663.
8. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
9. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virologica, 1961; 5:265-273.
10. Henry JL, Jaikaran ES, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: Excretion following challenge with live virus by children given killed or living poliovaccine. Journal of Hygiene Cambridge, 1966; 64:105-120.
11. Public Health Laboratory Service. The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk, and Sabin vaccines. Monthly Bulletin of the Ministry of Health and Public Health Laboratory Service, 1965; 24:365-369.
12. Minor PD. The molecular biology of poliovaccines. Journal of General Virology, 1992; 73(pt 12):3065-3077.
13. Mueller S, Wimmer E, Cello J. Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event. Virus Research, 2005; 111(2):175-193.
14. Jegouic S, Joffret ML, Blanchard C, Riquet FB, Perret C, Pelletier I, Colbere-Garapin F, Rakoto-Andrianarivelo M, Delpeyroux F. Recombination between polioviruses and co-circulating coxsackie A viruses: Role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathogens, 2009; 5(5):e1000412.
15. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, Andre J, Blackman E, Freeman CJ, Jorba J, Sutter R, Tambini G, Venczel L, Pedreira C, Laender F, Shimizu H, Yoneyama T, Miyamura T, van Der Avoort H, Oberste MS, Kilpatrick D, Cochi S, Pallansch M, de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 2002; 296(5566):356-359.
16. Estivariz CF, Watkins M, Handoko D, Rusipah R, Deshpande J, Rana BJ, Irawan E, Widhiastuti D, Pallansch MA, Thapa A, Imari S. A large vaccine-derived poliovirus outbreak on Madura island-Indonesia, 2005. Journal of Infectious Diseases, 2008; 197(3):347-354.
17. Kew O, Wright P, Agol V, Delpeyroux F, Shimizu H, Nathanson N, Pallansch M. Circulating vaccine-derived polioviruses: Current state of knowledge. Bulletin of the World Health Organization, 2004; 82:16-23.
18. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 2005; 59:587-635.
19. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One, 2008; 3(10):e3433.
20. Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine, 2009; 27(20):2649-2652.
21. Yang C, Naguib T, Yang S, Nasr E, Jorba J, Ahmed N, Campagnoli R, van der Avoort HGAM, Shimizu H, Yoneyama T, Miyamura T, Pallansch MA, Kew OM. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. Journal of Virology, 2003; 77(15):8366-8377.
22. Martin J, Ferguson GL, Wood DJ, Minor PD. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology, 2000; 278(1):42-49.
23. Kostrewski J, Kulesza A, Abgarowicz A. The epidemic of type 3 poliomyelitis in Poland in 1968. Epidemiologic Reviews (Warsaw), 1970; 24:89-103.
24. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI. Retrospective analysis of a local cessation of vaccination against poliomyelitis: A possible scenario for the future. Journal of Virology, 2003; 77(23):12460-12465.
25. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
26. World Health Organization. Circulating vaccine-derived poliovirus, 2000-2011. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx, Accessed on August 22, 2012.
27. World Health Organization. Global Polio Eradication Initiative-Strategic Plan 2010-2012. Geneva, 2010. Report No.: WHO/Polio/10.01.
28. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, September 21-22, 2004. Weekly Epidmiological Record, 2004; 79(45):401-408.
29. World Health Assembly. Poliomyelitis: Mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization, 2008. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf.
30. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape Journal of Medicine, 2008; 10(8):190.
31. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases, 1991; 163:1-6.
32. Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch MA, Kew OM. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. Journal of Infectious Diseases, 2011; 203(7):898-909.
33. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2009-March 2011. Morbidity and Mortality Weekly Report, 2011; 60(25):846-850.
34. Kew OM. Reaching the last one per cent: Progress and challenges in global polio eradication. Current Opinion in Virology, 2012; 2:188-198.
35. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nature Reviews Microbiology, 2007; 5(12):952-958.
36. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
37. Wagner BG, Earn DJ. Circulating vaccine derived polio viruses and their impact on global polio eradication. Bulletin of Mathematical Biology, 2008; 70(1):253-280.
38. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
39. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. Morbidity and Mortality Weekly Report, 2009; 58(36):1002-1006.
40. World Health Organization. Summary of Discussions and Recommendations, 16th Informal Consultation of the Global Polio Laboratory Network, September 22-23, 2010, WHO/HQ. Geneva: World Health Organization, 2010.
41. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, April 2011-June 2012. Morbidity and Mortality Weekly Report, 2012; 61(37):741-746.
42. Alexander JP, Jr., Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, Cebelinkski EA, Chen Q, Jorba J, Kew OM, Pallansch MA, Oberste MS, Schleiss M, Davis JP, Warshawsky B, Squires S, Hull HF. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. Journal of Infectious Diseases, 2009; 199(3):391-397.
43. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. Journal of Virology, 2008; 82(9):4429-4440.
44. Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. Journal of General Virology, 1981; 56(Pt 2):337-347.
45. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. Journal of Virology, 1989; 63(11):4949-4951.
46. Equestre M, Genovese D, Cavalieri F, Fiore L, Santoro R, Perez Bercoff R. Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. Journal of Virology, 1991; 65(5):2707-2710.
47. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD. The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology, 1991; 181(2):451-458.
48. Muzychenko AR, Lipskaya G, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI. Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: Structural and functional implications. Virus Research, 1991; 21(2):111-122.
49. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. Journal of Virology, 1991; 65(3):1377-1382.
50. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology, 1993; 192(1):18-26.
51. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine, 1994; 12(6):503-507.
52. Agol VI. Vaccine-derived polioviruses. Biologicals, 2006; 34(2):103-108.
53. Cuervo NS, Guillot S, Romanenkova N, Combiescu M, Aubert-Combiescu A, Seghier M, Caro V, Crainic R, Delpeyroux F. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. Journal of Virology, 2001; 75(13):5740-5751.
54. Liu HM, Zheng DP, Zhang LB, Oberste MS, Kew OM, Pallansch MA. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. Journal of Virology, 2003; 77(20):10994-11005.
55. Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. Journal of Virology, 2000; 74(18):8434-8443.
56. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, Randriamanalina B, Guillot S, Balanant J, Mauclère P, Delpeyroux F. Recombinant vaccine-derived poliovirus in Madagascar. Emerging Infectious Diseases, 2003; 9(7):885-887.
57. Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, Utama A, Tano Y, Arita M, Yoshida H, Yoneyama T, Benegas A, Roesel S, Pallansch MA, Kew OM, Miyamura T. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. Journal of Virology, 2004; 78(24):13512-13521.
58. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ. Basic concepts in RNA virus evolution. FASEB Journal, 1996; 10(8):859-864.
59. Agol VI. Molecular mechanisms of poliovirus variation and evolution. Current Topics in Microbiology and Immunology, 2006; 299:211-259.
60. Pfeiffer JK, Kirkegaard K. Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain. Proceedings of the National Academy of Sciences of the United States of America, 2006; 103(14):5520-5525.
61. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature, 2006; 439(7074):344-348.
62. World Health Organization. WHO Expert Committee on Biological Standardization-Thirty-Third Report. Geneva, Switzerland, 1983.
63. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology, 1938; 27(3):493-497.
64. Domingo E, Biebricher CK, Eigen M, Holland JJ, Corporation E. Quasispecies and RNA Virus Evolution: Principles and Consequences. Austin, TX: Landes Bioscience, 2001.
65. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology, 2010; 172(11):1213-1229.
66. Bernier RH. Some observations on poliomyelitis lameness surveys. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S371-S375.
67. Shelokov A, Habel K, McKinstry DW. Relation of poliomyelitis virus types to clinical disease and geographic distribution: A preliminary report. Annals of the New York Academy of Science, 1955; 61(4):998-1004.
68. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. Journal of the American Medical Association, 2004; 292(14):1696-1701.
69. Nkowane BM, Wassilak SGF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Journal of the American Medical Association, 1987; 267(10):1335-1340.
70. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases, 1992; 14:568-579.
71. Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: Decreased risk despite massive use of oral polio vaccine. Bulletin of the World Health Organization, 2002; 80(3):210-216.
72. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases, 2001; 33(4):531-541.
73. Dömök I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S413-S418.
74. Estívariz CF, Molnár Z, Venczel L, Kapusinszky B, Zingeser JA, Lipskaya GY, Kew OM, Berencsi G, Csohán Á. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. American Journal of Epidemiology, 2011; 174(3):316-325.
75. Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y, Genba Y, Nakano Y, Imura N. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proceedings of the National Academy of Sciences of the United States of America, 1982; 79(19):5793-5797.
76. Stanway G, Hughes PJ, Mountford RC, Reeve P, Minor PD, Schild GC, Almond JW. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proceedings of the National Academy of Sciences of the United States of America, 1984; 81(5):1539-1543.
77. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. Journal of Virology, 1995; 69(8):4972-4978.
78. Horie H, Koike S, Kurata T, Sato-Yoshida Y, Ise I, Ota Y, Abe S, Hioki K, Kato H, Taya C, Nomura T, Hashizume S, Yonekawa H, Nomota A. Transgenic mice carrying the human poliovirus receptor: New animal models for study of poliovirus neurovirulence. Journal of Virology, 1994; 68(2):681-688.
79. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. Journal of Virology, 1989; 63(3):1302-1309.
80. Martin A, Benichou D, Couderc T, Hogle JM, Wychowski C, Van der Werf S, Girard M. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology, 1991; 180(2):648-658.
81. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E, Nomoto A. Genetic analysis of the attenuation phenotype of poliovirus type 1. Journal of Virology, 1986; 58(2):348-358.
82. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. Journal of Virology, 1993; 67(8):4630-4638.
83. Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ. A mutation present in the amino terminus of Sabin 3 poliovirus VP 1 protein is attenuating. Journal of Virology, 1992; 66(5):3194-3197.
84. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. Journal of Virology, 1989; 63(3):1338-1344.
85. Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, Horaud F. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. Journal of Virology, 1990; 64(10):4922-4929.
86. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. Journal of Medical Virology, 1990; 32(2):92-95.
87. Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N, Minor PD. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology, 1989; 172(2):408-414.
88. Minor PD, Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. Journal of General Virology, 1988; 69(Pt 5):1091-1096.
89. Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. Journal of General Virology, 1986; 67(Pt 4):693-706.
90. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DM, Schild GC, Almond JW. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Research, 1984; 12(20):7787-7792.
91. Li J, Zhang LB, Yoneyama T, Yoshida H, Shimizu H, Yoshii K, Hara M, Nomura T, Yoshikura H, Miyamura T, Hagiwara A. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Archives of Virology, 1996; 141(6):1047-1054.
92. Lipskaya GY, Muzychenko AR, Kutitova OK, Maslova SV, Equestre M, Drozdov SG, Bercoff RP, Agol VI. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. Journal of Medical Virology, 1991; 35(4):290-296.
93. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, Crainic R. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Developments in Biolological Standardization, 1993; 78:33-38.
94. Friedrich F, Filippis AM, Ferreira FC, Oliveira MJ, Schatzmayr HG, Da-Silva EE. Poliovirus type 1 isolated from a vaccine-associated case of paralytic poliomyelitis in Brazil. Brazilian Journal of Medical and Biological Research, 1996; 29(1):15-18.
95. Friedrich F, Filippis AM, Ferreira FC, Schatzmayr HG, Da Silva EE. Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil. Acta Virologica, 1995; 39(1):23-29.
96. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology, 1993; 196(1):199-208.
97. Georgescu M-M, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F. Evolution of the Sabin type 1 poliovirus in humans: Characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. Journal of Virology, 1997; 71(10):7758-7768.
98. Georgescu MM, Delpeyroux F, Crainic R. Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. Journal of General Virology, 1995; 76(Pt 9):2343-2348.
99. Kapusinszky B, Molnar Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology, 2010; 58(2):211-217.
100. Liang X, Zhang Y, Xu W, Wen N, Zuo S, Lee LA, Yu J. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. Journal of Infectious Diseases, 2006; 194(5):545-551.
101. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. Journal of General Virology, 2002; 76(23):6791-6799.
102. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology, 1999; 265(2):178-184.
103. Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, Soresina AR, Vivarelli R, Delpeyroux F, Martín J, Fiore L. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. Journal of General Virology, 2003; 84(Pt 5):1215-1221.
104. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. Journal of Clinical Microbiology, 1998; 36(10):2893-2899.
105. Martín J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. Journal of Virology, 2000; 74(7):3001-3010.
106. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: A unifying model. Journal of Virology, 2000; 74(16):7381-7390.
107. Contreras G, Dimock K, Furesz J, Gardell C, Hazlett D, Karpinski K, McCorkle G, Wu L. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals, 1992; 20(1):15-26.
108. Lu Z, Rezapkin GV, Douthitt MP, Ran Y, Asher DM, Levenbook IS, Chumakov KM. Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. Journal of General Virology, 1996; 77(Pt 2):273-280.
109. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology, 1994; 202(1):370-378.
110. Assaad F, Cockburn W. The relation between acute persisting spinal paralysis and poliomyelitis vaccine-Results of a ten-year enquiry. Bulletin of the World Health Organization, 1982; 60:231-242.
111. McGoldrick A, Macadam AJ, Dunn G, Rowe A, Burlison J, Minor PD, Meredith J, Evans DJ, Almond JW. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. Journal of Virology, 1995; 69(12):7601-7605.
112. Laassri M, Lottenbach K, Belshe R, Rennels M, Plotkin S, Chumakov K. Analysis of reversions in the 5′-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases, 2006; 193(10):1344-1349.
113. Yang C-F, Chen H-Y, Jorba J, Sun H-C, Yang S-J, Lee H-C, Huang Y-C, Lin T-Y, Chen P-J, Shimizu H, Nishimura Y, Utama A, Pallansch MA, Miyamura T, Kew OM, Yang J-Y. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. Journal of Virology, 2005; 79(20):12623-12634.
114. Pavilanis V, Lussier G, Foley AR, Charbonneau JH, Difranco E, Dubreuil R. A study of Sabin type 1 oral vaccine virus during five human passages. Revue Canadienne de Biologie, 1964; 23:265-276.
115. Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. Journal of Medical Virology, 2005; 75(1):153-160.
116. Matsuura K, Ishikura M, Yoshida H, Nakayama T, Hasegawa S, Ando S, Horie H, Miyamura T, Kitamura T. Assessment of poliovirus eradication in Japan: Genomic analysis of polioviruses isolated from river water and sewage in Toyama prefecture. Applied and Environmental Microbiology, 2000; 66(11):5087-5091.
117. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. Journal of General Virology, 2002; 83(Pt 5):1107-1111.
118. Dane DS, Dick GWA, Briggs M, Nelson R, McAlister J, Conolly JH, Haire M, McKeown CMB. Vaccination against poliomyelitis with live virus vaccines: 6. Changes in Sabin type II oral vaccine virus after human passage. British Medical Journal, 1961; 2(5247):259-265.
119. Weeks-Levy C, Tatem JM, DiMichele SJ, Waterfield W, Georgiu AF, Mento SJ. Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology, 1991; 185(2):934-937.
120. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV, Jr. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature, 1985; 314(6011):548-550.
121. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999; 150(10):1001-1021.
122. Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. Molecular epimdemiology of polioviruses. Seminars in Virology, 1995; 6:401-414.
123. van der Sanden S, Pallansch MA, van de Kassteele J, El-Sayed N, Sutter RW, Koopmans M, van der Avoort HGAM. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. Journal of Virology, 2009; 83(17):8693-8704.
124. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 2013; 33(4):703-749.
125. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Poliovirus Vaccine Viruses: Implications for the Global Poliomyelitis Eradication Initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene, 1998 May.
126. Sutter RW, Suleiman AJM, Malankar PG, Mehta FR, Medany MA, Arif MAM, Linkins RW, Pallansch MA, ElBualy MS, Robertson SE. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases, 1997; 175:S235-S240.
127. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-Worldwide, January 2006-August 2007. Morbidity and Mortality Weekly Report, 2007; 56(38):996-1001.
128. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses. Morbidity and Mortality Weekly Report, 2006; 55(40):1093-1097.
129. Yan D, Li L, Zhu S, Zhang Y, An J, Wang D, Wen N, Jorba J, Liu W, Zhong G, Huang L, Kew O, Liang X, Xu W. Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China. Journal of Clinical Microbiology, 2010; 48(9):3274-3280.
130. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, Balanant J, Andriamamonjy SN, Rabemanantsoa S, Birmingham M, Randriamanalina B, Nkolomoni L, Venter M, Schoub BD, Delpeyroux F, Reynes JM. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. Journal of Infectious Diseases, 2008; 197(10):1427-1435.
131. Joffret ML, Jegouic S, Bessaud M, Balanant J, Tran C, Caro V, Holmblat B, Razafindratsimandresy R, Reynes JM, Rakoto-Andrianarivelo M, Delpeyroux F. Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children. Journal of Infectious Diseases, 2012; 205(9):1363-1373.
132. Combelas N, Holmblat B, Joffret ML, Colbere-Garapin F, Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: A model of viral genetic plasticity and emergence. Viruses, 2012; 3(8):1460-1484.
133. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Morbidity and Mortality Weekly Report, 2004; 53(42):990-993.
134. World Health Organization. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Weekly Epidemiological Record, 2004; 79(44):393-398.
135. Combiescu M, Guillot S, Persu A, Baicus A, Pitigoi D, Balanant J, Oprisan G, Crainic R, Delpeyroux F, Aubert-Combiescu A. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Archives of Virology, 2007; 152(4):727-738.
136. World Health Organization. Progress towards global poliomyelitis eradication-The approaching extinction of wild poliovirus type 2. Weekly Epidemiological Record, 1999; 74(34):286-288.
137. World Health Organization. Transmission of wild poliovirus type 2-Apparent global interruption. Weekly Epidemiological Record, 2001; 76:95-97.
138. World Health Organization. Incidence series. 2012. Available at: http://www.who.int/entity/immunization_monitoring/data/incidence_series.xls, Accessed on April 6, 2012.
139. Zhang J, Zhang LB, Otten MW, Jr., Jiang T, Zhang XL, Zhang RZ, Wang KA. Surveillance for polio eradication in the People's Republic of China. Journal of Infectious Diseases, 1997; 175(Suppl 1):S122-S134.
140. Jiang HF, Yan DM, Zhu SL, Wang DY, Zhang Y, Zhu H, An HQ, Xu WB, Kong XH. [Analysis of genetic characteristics of type II non-wild poliovirus in mainland China, 2010]. Bing Du Xue Bao, 2012; 28(2):130-135.
141. Zhang Y, Yan D, Zhu S, Wen N, Li L, Wang H, Liu J, Ye X, Ding Z, Wang D, Zhu H, Chen L, Hou X, An H, Liang X, Luo H, Kew O, Xu W. Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in China: Current immunization strategy effectively prevented its sustained transmission. Journal of Infectious Diseases, 2010; 202(12):1780-1788.
142. Adu F, Iber J, Bukbuk D, Gumede N, Yang SJ, Jorba J, Campagnoli R, Sule WF, Yang CF, Burns C, Pallansch M, Harry T, Kew O. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Research, 2007; 127(1):17-25.
143. Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, Fitzharris C, Butler K, Hall WW, Minor PD. Long-term excretion of vaccine-derived poliovirus by a healthy child. Journal of Virology, 2004; 78(24):13839-13847.
144. Rakoto-Andrianarivelo M, Guillot S, Iber J, Balanant J, Blondel B, Riquet F, Martin J, Kew O, Randriamanalina B, Razafinimpiasa L, Rousset D, Delpeyroux F. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathogens 2007; 3(12):e191.
145. World Bank. World Bank list of economies (July 2002). Available at: http://www.worldbank.org/data/databytopic/CLASS.XLS, Accessed on December 2002.